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Abstract 
 
Venous thromboembolisms (VTEs) are blood clots that begin in a vein and include deep venous 
thromboses (DVTs) and pulmonary embolisms (PEs). VTEs will affect an estimated 71 out of 
every 100,000 individuals yearly, with 100,000 to 300,000 deaths being attributable to VTEs 
every year, accounting for 10% of all hospital deaths, killing more people than AIDS, cancer, 
and auto accidents combined. Ultimately, VTEs are considered the most preventable hospital 
acquired condition. Using Cerner (an electronic health record) based data, this study investigates 
the impact of standardizing medication administration times (SMAT). A Chi Square test was 
used to examine the impact of this intervention. Findings suggest that the SMAT intervention 
both reduced the percent of pharmacological anticoagulation missed doses as well as the relative 
rate of patient refusals. This study also proposes a comprehensive VTE reeducation initiative, 
detailing the structure and evaluation of the initiative as well. The reeducation initiative improves 
two aspects of the iron triangle, namely improving patient quality and containing costs for VTE 
treatment, illustrating the public health relevance of the study.  
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1.0 INTRODUCTION 
 
 
 
 
1.1 LITERATURE REVIEW AND CURRENT STATE 
 
Venous thromboembolisms (VTEs) are blood clots that begin in a vein and include deep venous 
thromboses (DVTs) and pulmonary embolisms (PEs).  A DVT refers to a clot deep within a vein. 
DVTs usually occur in the leg, however, they can also affect arms or other veins in the body. A 
PE refers to a situation when a clot breaks free and travels to the lungs, blocking a portion or all 
of the blood supply. The most frequent reason for a VTE to occur is due to a DVT in the leg 
breaking off and traveling to the lungs. 
VTEs impact an estimated 71 out of every 100,000 individuals yearly (Heit et al., 2001) 
with approximately one third these individuals having a PE and two thirds have a DVT alone 
(White, 2003). The incident rate for VTE increases with other factors such as age, which has 
been associated in an increased incidence of 500 per 100,000 individuals over the age of 70 years 
(ISTH Steering Committee for World Thrombosis Day, 2014). The incidence rate of PE (with or 
without the presence of a DVT) was found to be 23 per 100,000 with an incidence of 48 per 
100,000 for a DVT alone being present (Anderson et al., 1991). VTE has been associated with 
significant morbidity and mortality. Importantly, the management of VTE is correlated with 
significant health care costs for both initial hospitalization as well as readmission (LaMori, 
Shohieber, Mody & Bookhart, 2015; see also Spyropoulos & Lin, 2007). 
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Postoperative VTEs are a specific category of VTEs for which insurers do not reimburse 
for services, resulting in a significant financial burden for hospitals. The Agency for Healthcare 
Research and Quality (AHRQ) defines a PSI-12 (Patient Safety Indicator 12) as: 
Perioperative pulmonary embolism or proximal deep vein thrombosis (secondary 
diagnosis) per 1,000 surgical discharges for patients ages 18 years and older. Excludes 
discharges with a principal diagnosis of pulmonary embolism or proximal deep vein 
thrombosis; with a secondary diagnosis of pulmonary embolism or proximal deep vein 
thrombosis present on admission; in which interruption of the vena cava or a pulmonary 
arterial thromboectomy occurs before or on the same day as the first operating room 
procedure; with extracorporeal membrane oxygenation; with acute brain or spinal injury 
present on admission; and obstetric cases (AHRQ Quality Indicators™ (AHRQ QI™) 
ICD-10-CM/PCS Specification, 2018). 
Currently, the rate of PSI-12s across the UPMC system is 5.46 per 1000 qualifying admissions, 
while the rate of PSI-12s for UPMC Magee-Womens Hospital is 3.64. The most current national 
rate of PSI-12s is 3.46 per 1000 qualifying admissions (see Figure 1 for a graph depicting 
February 2017 through January 2019 PSI-12 data specific to UPMC Magee-Womens Hospital). 
As a system, UPMC has an opportunity to improve this quality measure, as does UPMC Magee-
Womens Hospital. PSI-12s both impact patient care and the system’s reimbursement through 
reductions in payments for Medicare/Medicaid services. Naturally, it negatively impacts the 
reputation of the organization as well. The cost of a postoperative VTE is estimated to be 
approximately $15,123, which means that, based on the most current data available, UPMC 
Magee-Womens Hospital spent $483,936.00 on non-reimbursable care between February 2017 
and January 2018. For all of these reasons, a stronger education program needs to be established 
to improve the rate of postoperative VTEs.
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Figure 1. Graph Demonstrating the Rate of PSI-12s per 1000 Surgical Cases for UPMC Magee-Womens Hospital
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1.1.1 Literature Review: Education 
The goal of this paper is to take a nuanced look at the SMAT intervention as well as take a 
prospective look at the VTE education initiative being implemented at UPMC Magee-Womens 
Hospital. Multiple studies have found that 10-12 percent of anticoagulation doses prescribed for 
VTE prophylaxis are not administered to patients, with the most common reason for this being 
patient refusals (Shermock et al., 2013; Fanikos et al., 2010; see also Lau et al., 2017). Although 
a patient may refuse any type of care if they choose to do so, it is the responsibility of healthcare 
providers to educate patients so that their choice is knowledge based (Lau et al., 2017). Studies 
have shown that some nurses individually make the clinical decision regarding efficacy and 
appropriateness of the prescribed pharmacological VTE prophylaxis regiment (Elder et al., 2016; 
see also Lau et al., 2017). Specifically, Elder et al. (2016) found that low performing floor units 
contained nurses that were, “more likely to believe that pharmacological venous 
thromboembolism prophylaxis is ordered for patients who do not require it.” In addition to this 
barrier to care, despite the availability of evidence-based effective prophylaxis for treating VTEs, 
many studies have demonstrated that VTE prophylaxis is underutilized in hospitals (Goldhaber, 
Tapson, and VTE FREE Steering Committee, 2004; Cohen et al., 2008; see also Lau et al., 
2017). 
One possible reason for underutilization of VTE prophylaxis is inadequate education 
across nurses and clinical staff throughout the hospital. Studies have found that approximately 70 
percent of clinical nurses identified as good/fair level of knowledge about VTE risk assessments, 
however, this same group of nurses was not confident enough to perform VTE risk assessments 
themselves (Oh, Boo, and Lee, 2016). An additional study investigating VTE based 
knowledge/compliance among a group of nurses reported that approximately 65% of these 
nurses had accurate knowledge of the proper practices regarding VTE prevention (Choi & Min, 
5 
2011). A recent study at Johns Hopkins Hospital found that education for nursing significantly 
improved medication administration practice, and specifically, the nurses found the interactive 
Dynamic model (an online interactive module) to be more, “engaging, enjoyable, and enable 
better patient engagement) (Lau et al., 2017). Therefore, an education-based initiative to improve 
nursing understanding of the VTE initiative and to improve compliance with evidence based best 
practices will be examined throughout this document. 
1.1.2 Current State: Education 
Contemporary UPMC system-wide VTE prevention education of new UPMC nurses is limited 
to 15 minutes of didactic instruction during nursing orientation (RNO), which is considerably 
less time than the 60 minutes that has been allotted to the current nursing staff under the VTE 
prevention education. However, it provides a useful cursory introduction to the concept of the 
importance of VTE prevention. For patient care technicians (PCTs), on the other hand, UPMC-
wide education is provided for new PCTs at UPMC Mercy Hospital, called inexperienced 
nursing assistant (NA) class, which requires a competency completed on SCD use, application, 
and patient ambulation. However, it does not discuss cover proper documentation of these 
actions. Once the nurse and/or PCT completes their system-wide orientation, s(he) arrives at 
UPMC Magee-Womens Hospital for hospital specific orientation, also known as UPMC 
Beginnings. UPMC Beginnings does not presently include any additional VTE prevention 
education as the contents have been standardized and do not include significant clinical subject 
review due to time constraints. Following this, a nurse arrives on his or her unit and is assigned a 
preceptor, who oversees the nurse’s transition to independent care of the patient. This includes 
knowledge assessment of policies and procedures and observance of clinical skills. PCTs 
undergo a hospital-based PCT orientation before matching with their preceptor. Historically, unit 
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orientation has not focused on VTE prevention with formal emphasis, while hospital-based PCT 
orientation covered this topic, but did not provide necessary details regarding documentation or 
specific policy. In the past year, education has been more robustly featured at the unit-level, with 
encouragement and support proffered by nursing leadership and augmented by a nascent VTE 
champion group, however, the education has not made the necessary impact on compliance with 
VTE prevention best practice. Due to the persistent gaps in knowledge regarding VTE 
prevention, both pharmacologic and mechanical methods, this process flow for education of new 
nurses demonstrates there exists a perpetual cycle that reinforces a knowledge deficit, both 
clinically and in the realm of proper documentation in the electronic medical record. 
As previously noted, prior education efforts have focused on relying on VTE champions 
to provide education, who are floor nurses with added responsibilities for VTE prevention, with 
some support from unit leadership. VTE champions are nurses who choose to devote time to 
working on this effort and attend monthly meetings for the project. It is unrealistic to expect that 
these champions have the time to coordinate unit wide competency evaluations of nurses and 
PCTs, nor are standardized resources available from the system to provide this education to their 
nurses in a meaningful manner. In addition to this, VTE champions have no reasonable means to 
educate resource nurses or PCTS, who float across all medical/surgical units. 
Currently, all VTE related materials are dispersed to the various hospitals within UPMC 
from the Wolff Center, a centralized quality department for the system. In order to meet the 
needs of the system and account for some operating differences between hospitals, information 
and education is generalized accordingly. Without hospital-based education that specifies 
documentation and policy requirements, a new nurse has no formal, cohesive source of 
information they can work from to obtain this information. This realization is what ultimately 
spawned the VTE reeducation concept and development of this initiative. 
7 
In the flowchart below (Figure 2), green signifies the process is adequate, gray signifies 
that there is no education nor is it appropriate to provide education, yellow signifies possible 
education with opportunity for improvement, and red signifies a complete absence of education. 
Importantly, as previously noted, at no point in this education continuum is education sufficient 
to prepare a nurse to abide by proper VTE prophylactic intervention at UPMC Magee-Womens 
Hospital. Based on this flowchart, with preceptor nursing/PCT knowledge at various levels 
throughout the hospital, this cycle for education gaps is only widened. Ultimately, these multiple 
factors demonstrate why education efforts have previously been unsuccessful at producing a 
lasting effect of reducing the rate of VTEs. In addition, these factors demonstrate that there is a 
significant opportunity for improving the education process, which will be explored throughout 
this document
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Figure 2. Flowchart Depicting Possible Points of Education for Nurses (Left) and PCTs (Right) at UPMC 
Nurses PCTs 
Appropriate Education 
Opportunity for Improvement 
Absence of Education 
Not Appropriate for Education 
Appropriate Education 
Opportunity for Improvement 
Absence of Education 
Not Appropriate for Education 
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1.1.3 VTE Education Initiative: Organizational Structure 
UPMC-Magee Womens Hospital’s medical/surgical units consists of four units; 4100 
(orthopedics and bariatrics), 4800 (adult intensive care), 5300 (medicine), and 5800 
(gynecology oncology). In addition to this, there is a resource pool of nurses and PCTs which 
float between these various units. Each unit is managed by a unit director, who has multiple 
clinicians under them to delegate various tasks of management. To oversee the education of 
these nurses, there are 4 educators. One educator oversees 4800, one educator oversees 4100 
and 5800, one educator oversees 5300 and PCT new hire education, and the final educator 
oversees resource nurses and PCTs. The breakdown of the organizational structure that is 
relevant to the organizational structure can be found on Figure 3 (see following page):
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Figure 3. Flowchart Depicting Organization of Educator Responsibilities and Organizational Structure 
Note: All educators fall under the Director of Education as well as their individual units
CNO
Quality	Department
4100
Unit	Director
Clinician(s)
VTE	Champion(s)
4800
Unit	Director
Educator
Clinician(s)
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5300
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Educator
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VTE	Champion(s)
5800
Unit	Director
Educator
Clinician(s)
VTE	Champion(s)
Resource
Director
Educator
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1.1.4 VTE Education Initiative: Return on Investment Analysis 
The estimated cost of the VTE education initiative includes: educators’ time, administrators’ 
time, nurses time, and PCT’s time. It is estimated that it will take a maximum of 100 hours of 
educators’ time to perform the competencies, divided among 4 educators. The average cost of 
this time is $35.00 an hour, resulting in an approximate cost per hospital of 
$3,500. Conservatively, on average, units are staffed by 40 nurses and 20 PCTs, with UPMC 
Magee-Womens Hospital containing 4 medical/surgical units. In addition to this, there are 8 
nurses and 44 PCTs in a resource pool for these units. The education is estimated to take 30 
minutes of a nurse’s/PCT’s time, and the competency is estimated to take the same amount of 
time. Therefore, the estimated number of hours of nurse-time is estimated to be 168 hours and 
the estimated number of hours of PCT-time is estimated to be 204 hours. The average cost of this 
time is $30.00 an hour for nurses, resulting in an approximate cost of $5,040. The average hourly 
salary for a PCT is $13.00 an hour, resulting in an approximate cost of Quality managers are 
expected to utilize 0.3 FTE towards this initiative for a 3-month time frame. Using an average 
yearly salary of $100,000, the cost of a quality manager would be $7,500 per hospital. The total 
projected opportunity cost of this reeducation initiative is estimated to be $28,038. A summary 
of these costs can be found below in Table 1, including a 50% contingency (see following page):
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Table 1. Estimated Opportunity Costs of the VTE Education Initiative 
Employee Hours Hospital Cost 50% Contingency Cost 
Educator (4) 100 $3,500 $5,250 
Nurse (168) 168 $5,040 $7,560 
PCT (204) 204 $2,652 $3,978 
Quality Manager (1) 0.3 FTE $7,500 $11,250 
Total --- --- $28,038 
13 
The break-even analysis indicates that, in order to account for the cost of this education, a 
reduction of 2 postoperative VTEs would need to occur to experience a cost savings. This break-
even analysis does not include savings related to a higher star rating, brand recognition benefits 
of having better patient outcomes, nor other non-tangible benefits. In 2018, UPMC Magee-
Womens Hospital experienced 17 PSI-12 VTEs. If all PSI-12s could be prevented, UPMC 
Magee-Womens Hospital would see $229,053 in savings for non-reimbursable services in 
addition other benefits, after accounting for the cost of the initiative. If the goal of a 50% 
reduction in VTEs is met, UPMC Magee-Womens Hospital would see a cost savings of 
$100,508.50. The break-even analysis can be seen on the following page (Figure 2):
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Figure 4. Graph Depicting the Break-Even Analysis for PSI-12s per 1000 Surgical Cases for UPMC Magee-Womens Hospital
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1.1.5 Literature Review: Standardized Medication Administration Times (SMAT) 
Medication administration timing must account for both the complexity as well as the 
variability of medications, the indications for which the medications are being prescribed, the 
clinical situations for which the medications are being prescribed, and the needs of the patient 
receiving the medications. CMS has guided hospital policies and procedures to specifically 
address the timing of medication administration. Anticoagulant medications are eligible for 
scheduled dose timing within a hospital, due to wanting to achieve and maintain a therapeutic 
blood level of the anticoagulant in the patient over a specified period of time. Therefore, based 
on these guidelines as well as difficulties ensuring all doses of a scheduled dose medication are 
given, a Standardized Medication Administration Times (SMAT) intervention was developed to 
improve adherence of the medication administration process. 
According to the Institute for Safe Medication Practices, “Administer [medications 
administered more frequently than daily but not more frequently than every 4 hours] within 1 
hour before or after the scheduled time.” However, strict adherence to this rule would cause 
many medications to be rescheduled or missed, as a patient may be off of the unit or unable to 
receive the medication at that time. Therefore, Standardized Medication Administration Time 
(SMAT) was implemented in an effort to reduce the number of pharmacological anticoagulation 
missed doses of medication. The dosing schedule utilized by UPMC can be seen below: 
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Table 2. UPMC Standardized Dosing Schedule 
Standardized Dosing Times 
Interval Standard Times 
Daily 6A 
2 Times a Day (BID) 6A and 6P 
3 Times a Day (TID) 6A, 2P, and 10P 
This intervention applies only to prophylactic dosing of Lovenox (30mg Q24H, 30mg Q12H, 
40mg Q24H, or 40mg Q12H) and Heparin (5,000units BID or TID or 7,500units TID). In 
addition to this, this intervention is not intended to be used for subcutaneous therapeutic Heparin 
dosing used in obstetrical patients. 
Another critical component of the SMAT intervention is known as the “Half Dose 
Interval Rule.” If a patient is off of the unit, a nurse is to administer the medication upon return 
based on the following two points: 
• If at least half of the dosing interval remains give dose and do not change the
schedule.
• If greater than half the dosing interval, hold this dose and administer the next
scheduled dose.
A visual representation of this rule can be seen in Figure 3 on the following page:
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24-Hour Dosing Schedule:
6A 7A 8A 9A 10A 11A 12P 1P 2P 3P 4P 5P 6P 7P 8P 9P 10P 11P 12A 1A 2A 3A 4A 5A 
• A patient on a 24-hour dosing schedule can receive Lovenox late. The Lovenox can be administered as late as 12 hours
after the ordered administration time (i.e. half the dosing interval).
o Example: If a dose is given to a patient at 8A, the next dose can be given at 6A the following day without
delaying the medication administration.
• Note: Physician or pharmacist discussion encouraged if multiple doses could potentially be given within 12 hours of
each other OR if SMAT timing results in significant delay in administration (i.e. post op dose ordered at 9 am and not
entered to start until 6 am the next day because the MD didn’t specify the time).
12-Hour Dosing Schedule:
6A 7A 8A 9A 10A 11A 12P 1P 2P 3P 4P 5P 6P 7P 8P 9P 10P 11P 12A 1A 2A 3A 4A 5A 
• A patient on a 12-hour dosing schedule can receive Heparin/Lovenox late. The Heparin/Lovenox can be administered
as late as 6 hours after the ordered administration time (half the dosing interval).
o Example: If a dose is given to a patient at 8A, the following dose can be given to the patient at 6P.
• Note: Administering Lovenox twice within a 7-hour period could result in significant dose stacking. If necessary, this
can be done once or twice, but it should not be done consistently to avoid this risk. Physician discussion and/or
retiming encouraged if dosing is consistently late and being given with < 12 hours between dosing.
8-Hour Dosing Schedule:
6A 7A 8A 9A 10A 11A 12P 1P 2P 3P 4P 5P 6P 7P 8P 9P 10P 11P 12A 1A 2A 3A 4A 5A 
• A patient on an 8-hour dosing schedule can receive Heparin late. The Heparin can be administered as late as 4 hours
after the ordered administration time (half the dosing interval).
o Example: If a dose is given to a patient at 8A, the next dose can be given at 2P.
Figure 5. Visual Representation of the Half Dose Interval Rule
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1.2 STUDY CONTRIBUTIONS 
The goal of this paper is to take a nuanced look at the SMAT intervention as well as take a 
prospective look at the VTE education initiative. It is hypothesized that the SMAT intervention 
will 1) decrease the rate of pharmacological anticoagulation missed doses and 2) decrease the 
relative rate of patient refusals as the identified cause of pharmacological anticoagulation missed 
doses. The VTE education initiative is hypothesized to decrease the PSI-12 measure by 
positively impacting nursing compliance with the VTE initiative best practices and 
documentation. Limited research exists regarding the expected impact of a SMAT intervention, 
and therefore this knowledge will benefit the field of medication timing, extending beyond the 
VTE intervention. The VTE education initiative will examine the impact of a highly structured 
education initiative, which can be expanded system-wide if the impact of the program is great 
enough. The ROI and implications of this initiative are examined as well. Given the complexity 
of the Half Dose Interval Rule, an education effort may reinforce this initiative, and in turn 
improve the SMAT initiative further. In addition to this, a reduction in VTEs would ultimately 
have a significant public health impact on both patient safety and cost savings. 
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2.0 DATA AND METHODS 
2.1 ANTICOAGULATION DEFINITIONS 
This study used patient pharmacological anticoagulation data retrieved from Discern Reporting 
Portal, which is a reporting tool available in the Cerner electronic medical record.  The specific 
report utilized was Anticoagulation Meds Not Given.  This report retrieves all ordered doses of 
pharmacological anticoagulation that were not charted as given to a patient.  This report was set 
to pull information from specific units: 2600 (obstetric ICU), 2700/2800 and 3700/3800 
(pre/postpartum), 4100 (orthopedics and bariatric surgery), 4800 (adult ICU), 3200/5300 
(medicine), and 5800 (gynecological oncology).  Missed doses are categorized into one of eight 
categories: Not Done: Pt Refusal, Not Done: D/C Order, Not Done: Order/Task Duplication, Not 
Done: Not Appropriate at this Time (Details in Comments), Not Done: Held Per MD, Not Done: 
Pt Unavailable/Off Unit, Not Done: Held for Procedure, and Not Done: Other.  Six months of 
data immediately prior to the February SMAT implementation as well as six months of data post 
implementation was utilized to compile the dataset.  As the implementation occurred in 
February, the entire month of February was excluded from analysis. 
2.1.1 Not Done: Pt Refusal 
Patient refusals occur when a patient refuses his or her order for pharmacological 
anticoagulation. 
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2.1.2 Not Done: D/C Order 
An order is categorized as “Not Done: D/C Order,” or discontinued orders, when a physician 
discontinues the prescription of the pharmacological anticoagulation for the patient.  This entry is 
excluded from analysis as it is not a missed dose. 
2.1.3 Not Done: Order/Task Duplication 
An order is categorized as “Not Done: Order/Task Duplication” when concurrent orders exist for 
pharmacological anticoagulation medication for a specified patient.  The duplicate entry is 
excluded from analysis as it is not a missed dose. 
2.1.4 Not Done: Not Appropriate at this Time (Details in Comments) 
An order is categorized as “Not Done: Not Appropriate at this Time (Details in Comments)” 
when some aspect of the patient’s care prevents the pharmacological anticoagulation from being 
administered. 
2.1.5 Not Done: Held Per MD 
An order is categorized as “Not Done: Held Per MD” when a physician or advanced care 
practitioner orders the medication be held for a specific patient. 
2.1.6 Not Done: Pt Unavailable/Off Unit 
An order is categorized as “Not Done: Pt Unavailable/Off Unit” when a patient was not on the 
unit at the time the pharmacological anticoagulation dose was to be administered. 
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2.1.7 Not Done: Held for Procedure 
An order is categorized as “Not Done: Held for Procedure” when an upcoming procedure, such 
as a surgical procedure, prevents the pharmacological anticoagulation from being administered to 
the patient. 
2.1.8 Not Done: Other 
An order is categorized as “Not Done: Other” when it cannot be categorized into any of the other 
eight categories of pharmacological anticoagulation missed doses. 
2.2 STATISTICAL ANALYSES 
A Chi-Square Goodness of Fit test (Chi-Square test) was used to examine the effect of the 
SMAT intervention. The implementation of SMAT is hypothesized to decrease the percent of 
pharmacological anticoagulation missed doses. Furthermore, as refusals of anticoagulation are 
the most common reasons for a dose being missed, a Chi-Square test was used to examine 
whether the relative percent of refusals was impacted by the implementation of SMAT. Lastly, 
the Odds Ratio for the refused doses of anticoagulation was examined to better understand the 
results of the statistical analysis. 
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3.0 RESULTS 
3.1 SAMPLE DESCRIPTIVE STATISTICS OF MISSED DOSES OF 
PHARMACOLOGICAL ANTICOAGULATION 
The results indicated that the average percent of pharmacological anticoagulation missed doses 
was lower following the implementation of SMAT (See Table 3). During the time period from 
August 2017 to August 2018, the range of percent of pharmacological anticoagulation missed 
doses ranged from 5.48 percent to 9.84 percent, with an average of 8.51 percent of 
pharmacological anticoagulation missed doses occurring prior to the implementation of SMAT, 
and an average of 6.46 percent of pharmacological anticoagulation missed doses occurring after 
the implementation of SMAT occurred.  Figure 4 displays the percent of pharmacological 
anticoagulation missed doses over time, while Figure 5 displays the combined pharmacological 
anticoagulation missed doses prior to and following the SMAT intervention (6 months of data 
were included in each of these categories). 
3.2 SAMPLE DESCRIPTIVE STATISTICS OF REFUSED DOSES OF 
PHARMACOLOGICAL ANTICOAGULATION 
The results indicated that the average percent of patient refusals of pharmacological 
anticoagulation was lower following the implementation of SMAT (See Table 4). During the 
time period from August 2017 to August 2018, the range of percent of refused pharmacological 
anticoagulation doses ranged from 87.96 percent to 60.59 percent, with an average of 83.51 
percent of pharmacological anticoagulation missed doses occurring prior to the implementation 
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of SMAT, and an average of 73.37 percent of pharmacological anticoagulation missed doses 
occurring after the implementation of SMAT occurred.  Figure 6 displays the relative percent of 
refused pharmacological anticoagulation doses over time, while Figure 7 displays the combined 
refused pharmacological anticoagulation doses prior to and following the SMAT intervention (6 
months of data were included in each of these categories).  
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Table 3. Distribution of Missed Doses by Month and Pre-Post Period  
Pre (N=14,461) Post (N=12,561) 
Variables Missed Doses Total Doses % of Missed Doses Missed Doses Total Doses % of Missed Doses 
August 2017 235 2387 9.84% --- --- --- 
September 2017 206 2588 7.96% --- --- --- 
October 2017 242 2444 9.90% --- --- --- 
November 2017 191 2466 7.75% --- --- --- 
December 2017 206 2103 9.80% --- --- --- 
January 2018 151 2473 6.11% --- --- --- 
February 2018 --- --- --- --- --- --- 
March 2018 --- --- --- 122 1990 6.13% 
April 2018 --- --- --- 124 2262 5.48% 
May 2018 --- --- --- 130 2017 6.45% 
June 2018 --- --- --- 124 1990 6.23% 
July 2018 --- --- --- 141 2094 6.73% 
August 2018 --- --- --- 170 2208 7.70% 
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Figure 6. Graph Displaying the Percent of Total Missed Doses per Month from August 2017 to August 2018 
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Figure 7. Graph Displaying the Percent of Missed Prior to and Following the SMAT Intervention from August 2017 to August 
2018 
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Table 4. Distribution of Refused Doses by Month and Pre-Post Period  
Pre (N=14,461) Post (N=12,561) 
Variables Refused Doses 
Total Missed 
Doses 
% of Missed 
Doses 
Refused 
Doses 
Total Missed 
Doses 
% of Missed 
Doses 
August 2017 194 235 82.55% --- --- --- 
September 
2017 169 206 82.04% --- --- --- 
October 2017 211 242 87.19% --- --- --- 
November 2017 168 191 87.96% --- --- --- 
December 2017 179 206 86.89% --- --- --- 
January 2018 107 151 70.86% --- --- --- 
February 2018 --- --- --- --- --- --- 
March 2018 --- --- --- 103 122 84.43% 
April 2018 --- --- --- 101 124 81.45% 
May 2018 --- --- --- 96 130 73.85% 
June 2018 --- --- --- 93 124 75.00% 
July 2018 --- --- --- 99 141 70.21% 
August 2018 --- --- --- 103 170 60.59% 
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Figure 8. Graph Displaying the Percent of Refused Doses per Month from August 2017 to August 2018 
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Figure 9. Graph Displaying the Relative Percent of Missed Prior to and Following the SMAT Intervention from August 2017 
to August 2018 
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3.3 STATISTICAL ANALYSIS OF MISSED DOSES OF PHARMACOLOGICAL 
ANTICOAGULATION 
The post intervention period (M = 6.46%, SD = 0.0074) was found to have a lower percent of 
pharmacological anticoagulation missed doses than the pre intervention period (M=8.51%, SD = 
0.016). A Chi-Square test of independence was performed to examine the relation between 
SMAT intervention and pharmacological anticoagulation missed doses of pharmacological 
anticoagulation. The results of this relationship confirm that there was a statistically significant 
difference across the implementations (χ2(2, N = 27,022) = 40.68, p = 1.79 x 10-10). See Table 5 
for a detailed observed and expected results table. 
Table 5. Chi-Square Observed and Expected Results and Analysis of Missed Doses of 
Pharmacological Anticoagulation 
Pre Post Total 
Missed Dose 
Observed 1231 811 
2042 
Expected 1093 949 
Dose Given 
Observed 13230 11750 
24980 
Expected 13368 11612 
Total Doses Actual 14461 12561 27022 
P-Value 1.7947E-10 
Chi-Square 40.67830712 
3.4 STATISTICAL ANALYSIS OF REFUSED DOSES OF PHARMACOLOGICAL 
ANTICOAGULATION 
The post intervention period (M = 73.37%, SD = 0.085) was found to have a relatively lower 
percent of refused doses than the pre intervention period (M=83.51%, SD = 0.064). A Chi-
Square test of independence was performed to examine the relation between SMAT intervention 
and refused doses of pharmacological anticoagulation. The results of this relationship confirm 
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that there was a statistically significant difference across the implementations (χ2(2, N = 2,042) = 
30.84, p = 2.13 x 10-8, odds ratio = 0.53). The odds ratio is reported as a ratio of the pre group 
relative to the post group. 
Table 6 Chi-Square Observed and Expected Results and Analysis of Refused Doses of 
Pharmacological Anticoagulation 
Pre Post Total 
Missed Dose 
Observed 1028 595 
1623 
Expected 978 645 
Dose Given 
Observed 203 216 
419 
Expected 253 166 
Total Doses Actual 1231 811 2042 
P-Value 2.1283E-08 
Chi-Square 30.84223678 
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4.0 DISCUSSION 
4.1 PHARMACOLOGICAL ANTICOAGULATION DISCUSSION 
The first hypothesis regarding the SMAT intervention was that it would decrease the rate of 
pharmacological anticoagulation missed doses. The second hypothesis was that the SMAT 
intervention would decrease the relative rate of patient refusals as the identified cause of 
pharmacological anticoagulation missed doses. The results of Chi Square analysis supported both 
hypotheses. 
Standardizing the time of medication administration creates an expectation as well as a 
routine for nurses to follow when administering medications in the morning. As evidenced by the 
results of this study, this standardization has led to a significant decrease in pharmacological 
anticoagulation missed doses. In conjunction with this expectation is the Half Dose Interval 
Rule, which states that if a patient is off of the unit, a nurse is to administer the medication upon 
return based on the following two points: 
• If at least half of the dosing interval remains give dose and do not change the
schedule.
• If greater than half the dosing interval, hold this dose and administer the next
scheduled dose.
The Half Dose Interval Rule was initiated in an attempt to maintain the routine times of 
administration. Prior to this initiative being implemented, nursing could be giving patients doses 
of pharmacological anticoagulation at completely disjoint times of day, as the medication would 
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simply be rescheduled or missed if the ordered time for the medication was not feasible to 
administer the medication. These disjoint administration times ultimately lead to doses not being 
administered to the patient. By giving nursing a safe timeframe to administer the medication past 
the ordered administrative time while keeping the next scheduled dose of pharmacological 
anticoagulation unaltered, the routine administration times are maximized, less rescheduling 
needs to occur, and ultimately the percent of missed doses of pharmacological anticoagulation 
declines. 
In addition to reducing the percent of pharmacological anticoagulation missed doses, the 
initiative was found to reduce the relative percent of refused doses. Prior to this initiative, 
nursing could potentially reschedule a medication so that one of the administration times was 
2:00 in the morning. Patients are much more likely to refuse a dose, in particular a medication 
that must be injected, at a time when they want to be sleeping than 6:00 in the morning, when 
nursing is doing bloodwork anyway. The results of the odds ratio found that the pre 
implementation group relative to the post implementation group was 0.53, meaning that the post 
implementation group was approximately half as likely as the pre implementation group to 
refuse pharmacological anticoagulation. 
4.2 VTE EDUCATION INITIATIVE DISCUSSION 
The VTE education initiative discussion will be prospective, as the initiative has not yet 
occurred, and no data is available to examine. In order to standardize nursing knowledge and 
competency within the hospital, it is first necessary to create a standardized education toolkit 
nurses can read and reference when they are unsure of the proper treatment for one of their 
patients. This tool would have to cover topics identified by the system as best practice for VTE 
prevention. Generally, these topics include: patient education of VTE prevention, sequential 
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compression device (SCD) utilization, and ambulation policies of the system. In addition to these 
topics, understanding of pharmacologic DVT prophylaxis and proper documentation of these 
best practices are necessary to successfully care for a patient. After numerous meetings and 
rounding with various nursing units, an educational guide was created by the author of paper for 
this VTE education initiative (see Appendix A). 
4.3 VTE EDUCATION INITIATIVE PROPOSED STRUCTURE 
4.3.1 VTE Education Initiative: Proposed Structure: Part 1: Reeducation 
In the proposed structure to the VTE education initiative, a competency would be designed and 
utilized by nurse educators across all medical/surgical units of UPMC Magee-Womens Hospital. 
Nurse educators would be trained by their hospital’s quality manager using the evidence-based 
standardized curriculum, ensuring their knowledge and teaching style is standardized. Nurse 
educators would then take a one-month period to educate all of their staff through half hour small 
group sessions (5-10 nurses a session). One month later, nurse educators would return to 
complete competencies in an effort to validate the nurses understood the education. 
4.3.2 VTE Education Initiative: Proposed Structure: Part 2: New Hire Education 
Once the proposed VTE reeducation effort has been completed, a process for educating new 
hires must occur to prevent the knowledge gained by this initiative from regressing back to the 
previous state. Therefore, the second component of this VTE education initiative would be built 
into unit-based orientation as well as yearly competencies to ensure the education has had an 
enduring, consistent effect. 
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4.3.3 VTE Education Initiative: Proposed Structure: Part 3: Enforcement 
Once the proposed VTE reeducation effort and new hire education have been established, a 
process for enforcement of these policies must be put in place to ensure adherence to the 
evidence based best practices for VTE prevention. Therefore, the third component of this VTE 
education initiative would consist of tracking the competency validation of nurses as well as 
disciplining nurses who frequently are not meeting best practices for their patients. Competency 
validation forms can be sent to the hospital-based Quality Department, where tracking of 
competency completion may occur. Unit directors would be tasked with disciplining nurses who 
have completed the VTE competency yet continue to fail to meet best practices for VTE 
prevention. 
4.4 VTE EDUCATION INITIATIVE EVALUATION 
Once the VTE education initiative has been completed, a means of evaluation must be 
established the effectiveness of the intervention. There are multiple key performance indicators 
(KPIs) that are currently monitored by the Quality Department that could be utilized for this 
component of the initiative, which will be discussed in further detail below: 
4.4.1 Anticoagulation Missed Dose Report 
Once per week, floor units receive a report that identifies all missed doses of pharmacological 
anticoagulation and the reasons associated with each incident. In addition to this, units receive a 
monthly report that details the monthly percent of pharmacological anticoagulation missed doses, 
detailing a rolling two years of data. This information would be useful to examine following the 
implementation of this initiative. It would be hypothesized that the number of missed doses 
would decrease even further as knowledge of medications as well as the SMAT initiative 
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increases. It would also be hypothesized that the compliance with proper documentation of a 
pharmacological anticoagulation missed dose would increase after nursing has been educated. 
4.4.2 Quality Monitoring 
Floor units receive a monthly report detailing compliance across a variety of quality measures. 
From a VTE perspective, this report includes compliance audits of the following measures: 1) 
Whether VTE orders were addressed for patients on the floor; 2) Nursing charting on SCD 
orders; and 3) Visual audits of whether SCDs are actually being worn by patients. It would be 
hypothesized that all three of these measures would improve as knowledge of VTE prevention is 
standardized across nursing within the hospital. 
4.5 FUTURE STATE: EDUCATION 
Contemporary UPMC system-wide VTE prevention education of new UPMC nurses will 
continue to contain 15 minutes of didactic instruction during nursing orientation (RNO), in order 
to provide a useful cursory introduction to the concept of the importance of VTE prevention. As 
previously stated, patient care technicians (PCTs) will continue to receive new hire PCT 
education at UPMC Mercy Hospital, called inexperienced nursing assistant (NA) class, which 
requires a competency completed on SCD use, application, and patient ambulation. Once the 
nurse and/or PCT completes their system-wide orientation, s(he) will still arrive at UPMC 
Magee-Womens Hospital for UPMC Beginnings. Following this, a nurse will arrive on his or her 
unit and be assigned a preceptor while PCTs will continue to undergo a hospital-based PCT 
orientation before matching with their preceptor. Following the VTE reeducation 
implementation, unit orientation and hospital-based PCT orientation will now cover VTE 
prevention in detail, educating on details regarding documentation and specific policies. 
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Precepting nurses and precepting PCTs will now be better educated and have completed the VTE 
reeducation competency, better preparing the preceptor to educate on the topic of VTE 
prevention. VTE champions will continue to both audit and reinforce this education. The 
improved process flow can be seen on the following page (see Figure 10 on the following page):
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Figure 10. Flowchart Depicting the Improved Education Workflow for Nurses (Left) and PCTs (Right) at UPMC 
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4.6 PUBLIC HEALTH AND IRON TRIANGLE IMPLICATIONS 
Nearly everyone in healthcare is familiar with the Iron Triangle, which was first introduced in 
William Kissick’s book Medicine’s Dilemmas: Infinite Needs Versus Finite Resources in 1994 
(see Figure 10 below): 
 
 
Figure 11: Image Depicting the Iron Triangle Framework 
The Iron Triangle includes three key components: improving quality of care being delivered, cost 
containment, and expanding access to care. Ultimately, investments by healthcare organizations 
should seek to meet multiple aspects of this framework. The VTE reeducation initiative meets 
two aspects of this triangle, namely improving quality and containing costs. First, by improving 
compliance with best practices, the quality of care provided to patients is maximized, with high 
risk patients being identified, appropriately cared for, and being sent home with appropriate 
preventative medications to prevent readmissions. Second, the VTE reeducation initiative aims 
to reduce costs both of the organization as well as having implications for reducing the costs of 
healthcare generally. By reducing the rate of PSI-12s by 50%, over $100,000 of treatment costs 
can be avoided. When factoring in the cost of nonsurgical VTEs, single hospitals can prevent 
hundreds of thousands of healthcare dollars from being spent.
Improve 
Quality 
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Access 
Reduce 
Costs 
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4.7 LIMITATIONS 
The primary limitation of the present study was that this study was not possible to complete in 
isolation. There is information being distributed through multiple venues, and there are efforts 
being made to improve VTE prevention within the hospital setting. Feedback is constantly given 
to unit directors to pass on to their staff with the hopes of improvement. This could bias the 
results of the study, as these efforts could produce similar effects to the desired effect of the 
SMAT intervention. Nonetheless, the effect size was so strong that the author believes that the 
SMAT intervention would still likely be highly significant even if it were possible to test this 
intervention in isolation. Another limitation of this paper is that there was no data yet available 
on the VTE education initiative as it is currently in the process of being implemented. Once 
sufficient data has been collected, the impact of this initiative may be examined. 
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5.0 CONCLUSION 
Together, the findings of the SMAT initiative demonstrate that the program was a definite 
success. Not only was it successful at decreasing the percent of pharmacological anticoagulation 
missed doses, but it was successful at decreasing the relative rate of patient refusals as well. This 
program could arguably become more successful as the education initiative is implemented, as 
knowledge of the Half Dose Interval Rule will improve across nurses in the hospital setting. The 
VTE education initiative is an evidence-based program with potential to greatly impact nursing 
compliance with VTE prevention best practices. Future research is indicated to examine possible 
improvements to the SMAT intervention, specifically regarding the ideal times to administer 
medications. 
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APPENDIX A: VTE COMPETENCY VALIDATION FORM AND VTE EDUCATION 
PACKET 
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Educator: Name ___________________ Signature ___________________ Date ___________________ 
Nurse: Name ___________________ Signature ___________________ Date ___________________
Prior to Competency Validation All 
Prerequisite Reading Has Occurred 
Verbalizes 
(Date/Initials) 
Yes/No 
Demonstrates 
(Date/Initials) 
Yes/No 
Needs further 
review (Y/N) 
(Date/Initials) 
Comments 
Patient Education (PCTs can reiterate education by nursing) 
☐ Provide patient with VTE education on 
admission.
☐ Reeducate patient regarding VTE upon 
refusal.
SCDs 
☐ Selects Sequential Compression Device 
(SCD):
• Demonstrates sizing/application
• Verbalizes contraindications 
• Verbalizes skin assessment/care 
Ambulation 
☐ Describes minimum frequency.
☐ Describes acceptable minimum 
distance.
Pharmacologic DVT Prophylaxis (Nursing only) 
☐ Verbalizes Standardized Medication 
Administration Times (SMAT).
☐ Describes when medication should be 
re-scheduled.
☐ Verbalizes when medication should be 
held.
☐ Describes how to chart the correct 
“Reason Not Done” for medication 
administration.
VTE IPOC (Nursing only) 
☐ Describes location and purpose of IPOC.
☐ Verbalizes frequency of 
completion/revision.
Documentation 
☐ Demonstrates/verbalizes use of SCD 
Task
☐ Demonstrates/verbalizes use of 
IView/I&O
• Pharmacologic documentation and 
information requirements of
comments.
• SCD frequency and documentation.
• SCD application length of time.
• Ambulation frequency and 
documentation.
• Knowledge of proper ambulatory 
documentation of distance.
• VTE/Anticoagulation education. 
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VTE Education Packet 
 
Background: VTE Statistics:  
• 350,000-650,000 Americans are diagnosed with a VTE every year. 
• 100,000-300,000 deaths are related to VTEs every year. 
• VTEs account for 10% of all hospital deaths. 
• VTEs kill more people than AIDS, cancer, and car accidents combined! 
• VTE is the MOST preventable hospital acquired condition (HAC). 
Background: VTE Associated Costs: 
• Each hospital-associated DVT event costs, on average, $7,700-$10,800. 
• Each hospital associated PE event costs, on average, $9,500-$16,600. 
  
Three Questions Every Nurse Should Ask Himself/Herself: 
1) Did my patient refuse VTE prevention? If so, did I leave 
details in my documentation? 
2) Did I document SCDs and clear my pumps appropriately? 
3) Did I ambulate my patient twice today? 
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VTE Education Packet 
 
Section 1: Patient Education: 
• Upon admission, nurses are to provide their patients (and the patients’ families) with VTE education. 
• The Blood Clot Prevention Flier (see below) should be provided with the welcome guide for every 
patient. 
 
  
Blood Clots: What You Can Do to Prevent Them: 
 
You are at risk for a blood clot. Surgery, infections, lack of 
movement, and being in a hospital are risk factors for a blood 
clot. A blood clot is when blood does not flow normally through 
your blood vessels. This can be very serious and can even 
cause death.  Blood clots affect 900,000 Americans and are 
responsible for over 100,000 deaths each year.   
Other Names for Blood Clots: 
• Deep vein thrombosis (DVT) is a clot in the leg or arm. 
• Pulmonary embolism (PE) is a clot in the lungs. 
 
What You Can Do to Prevent a Blood Clot: 
• Take Medicines that Thin Your Blood (Called Anticoagulants): 
o You may need to get this medicine as shots, pills, or both. Please talk to your care 
team if this is not a good choice for you. 
• Use the Sequential Compression Device, or SCD: 
o Your doctor may recommend this machine to improve blood flow in your legs.  The 
sleeves wrap around your legs and connect to a machine that fills and then removes 
air from the sleeves.  
o It is very important to always use the machine when you are in bed or in a chair. Ask 
someone to remove the sleeves before walking. 
• Wear TED Hose: 
o These stockings are given to some patients to push blood toward their heart. 
• Walk/Exercise Your Legs: 
o Get out of bed and walk as many times a day as you can because 
exercise/movement helps your blood to flow. 
o Point your toes up to tighten your calves and then relax them. Do this as many times 
a day as you can. 
 
When you leave the hospital, you are still at risk.  It is important to take your 
medications, walk, and exercise your legs. 
 
Learn more about blood clot prevention by watching a video at 
www.UPMC.com/healthlibrary on your phone or when you get home.  Search for blood 
clot video in the search bar. Select “Preventing Blood Clots in Leg Veins Video.”  
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VTE Education Packet 
 
Section 1: Patient Education (Continued): 
• Upon refusal, patient (and family) should be reeducated regarding the importance of VTE Education. 
• If reeducation is unsuccessful and the patient continues to refuse, please make sure to reach out to the 
provider to see if they want the order D/Ced or if they want you to continue documenting the orders 
as "refused." 
 
 
Verbiage to Set You Up for Patient Acceptance: 
• Anticoagulation Medication Administration: “Mr. Jones, I have your Heparin/Lovenox injection that 
Dr. Smith ordered for you. You are at high risk of developing blood clots and this will help prevent you 
from getting one. I see that you had the last injection on the right side of your stomach. Apart from the 
right side, where would you like this injection to be?” 
o The above example still gives the patient a choice in their care, but also does not ask the patient 
if they want the medication, which could result in more patient refusals. 
• Anticoagulation Medication Refusal: “Mr. Jones, this injection is important to prevent you from 
developing a blood clot which can travel to your lungs and cause your condition to become worse or 
even lead to death.” 
o The above example ensures the patient understands the danger of refusing medications. 
• Anticoagulation Medication Refusal: “Mr. Jones, although walking helps prevent blood clots, it is 
important that we use all options to prevent you from developing a blood clot. If you are uncomfortable 
with getting this injection, I will call Dr. Smith and ask if there is an alternative medication you can 
use.” 
o The above example emphasizes the importance of a comprehensive VTE prevention plan as well 
as helps you appear to be attempting to customize their prevention plan to their interests. 
 
VTE Escalation Protocol: 
 
 
  
If	Patient	Still	Refuses,	Notify	the	Provider	and	Document	with	Whom	You	Spoke
Reiterate	the	Importance	of	VTE	Prevention	Therapy
Patient	Refuses	Anticoagulation,	SCDs	and/or	Mobility
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VTE Education Packet 
 
Section 2: Sequential Compression Devices (SCDs): 
• SCDs should be sized and applied appropriately by following the manufacturing guidelines. 
• SCDs should be removed during the head-to-toe assessment and skin integrity should be checked. 
 
General Application Guidelines for SCDs: 
• Determine the correct sleeve size by measuring the extremity of the patient. 
• The ankle should line up with the ankle indication on the sleeve. 
• Wrap the sleeve around the patient’s leg and secure it. 
• Rule of Thumb: Place two fingers between the patient’s leg and the sleeve to ensure a correct fit. 
• Check the connections are attached properly. 
• Turn the SCD pump on and ensure its working properly. 
• Goal: Patient should wear SCDs for 18 hours every 24-hour period. 
Contraindications: 
• If your patient is admitted with new-onset LE swelling and is awaiting testing to rule out a DVT, do not 
use an SCD on that extremity until the exam has been completed and is negative. 
• If the patient has a DVT in one LE, you can still apply an SCD to the opposing leg if appropriate. 
• If the patient, at any time during their stay, starts to complain of calf pain or has a Homan's sign, please 
remove the SCD and alert the provider to see if s/he wants to obtain a Doppler to rule out a DVT. 
• If the patient has had recent surgery on that extremity, SCDs should only be applied if cleared by a 
provider. 
• For cellulitis and wounds, unless stated otherwise by the provider, do not prohibit the use of SCDs. 
• If your patient has had an amputation of one extremity, the other extremity can still have an SCD 
applied if cleared by the provider. 
• Do not use SCDs in conjunction with TED hose.  
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Section 2: Sequential Compression Devices (SCDs) (Continued): 
 
 
*Though the image states EPIC, this applies to both Cerner and EPIC.  
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Section 3: Ambulation: 
• UPMC System Policy: Provided ambulation is not contraindicated, ambulation should occur and be 
documented BID. 
• SCDs may be removed while ambulating, however, they should immediately be reapplied once the 
patient returns to the bed or chair. 
• Ambulation is defined as the ability to walk for 32 feet (Amin, Girard, and Samama 2010). 
• Refusals: Per Section 1: Patient Education, the patient should be educated on the importance of 
ambulation. 
• Myth: I can’t ambulate my patient because he has a DVT. Studies have actually shown that ambulation 
reduces swelling and does not increase the chance that a patient will develop a PE. Only SCDs are 
contraindicated on the leg with an active DVT. 
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Section 4: Pharmacologic DVT Prophylaxis: 
• Note: This guide applies only to prophylactic dosing of Lovenox (30mg Q24H, 30mg Q12H, 40mg 
Q24H, or 40mg Q12H) and Heparin (5,000units BID or TID or 7,500units TID). This guide is NOT 
intended to be used for SubQ therapeutic Heparin dosing used in obstetrical patients. 
• Standard Medication Administration Times (SMAT) of Heparin and Lovenox: Strategy 
implemented to increase the number of anticoagulation doses given: 
o Daily: 6A 
o BID: 6A and 6P 
o TID: 6A, 2P, and 10P 
• ½ Dose Interval Rule: If patient is off the unit, administer the medication upon return. If at least half of 
the dosing interval remains give dose and do not change the schedule. If greater than half the dosing 
interval, hold this dose and administer the next scheduled dose. 
 
 
24-Hour Dosing Schedule: 
6A 7A 8A 9A 10A 11A 12P 1P 2P 3P 4P 5P 6P 7P 8P 9P 10P 11P 12A 1A 2A 3A 4A 5A 
• A patient on a 24-hour dosing schedule can receive Lovenox late. The Lovenox can be administered as 
late as 12 hours after the ordered administration time (i.e. half the dosing interval). 
o Example: If a dose is given to a patient at 8A, the next dose can be given at 6A the following 
day without delaying the medication administration. 
• Note: Physician or pharmacist discussion encouraged if multiple doses could potentially be given within 
12 hours of each other OR if SMAT timing results in significant delay in administration (i.e. post op 
dose ordered at 9 am and not entered to start until 6 am the next day because the MD didn’t specify the 
time). 
12-Hour Dosing Schedule: 
6A 7A 8A 9A 10A 11A 12P 1P 2P 3P 4P 5P 6P 7P 8P 9P 10P 11P 12A 1A 2A 3A 4A 5A 
• A patient on a 12-hour dosing schedule can receive Heparin/Lovenox late. The Heparin/Lovenox can 
be administered as late as 6 hours after the ordered administration time (half the dosing interval). 
o Example: If a dose is given to a patient at 8A, the following dose can be given to the patient at 
6P. 
• Note: Administering Lovenox twice within a 7-hour period could result in significant dose stacking. If 
necessary, this can be done once or twice, but it should not be done consistently to avoid this risk. 
Physician discussion and/or retiming encouraged if dosing is consistently late and being given with < 12 
hours between dosing. 
8-Hour Dosing Schedule: 
6A 7A 8A 9A 10A 11A 12P 1P 2P 3P 4P 5P 6P 7P 8P 9P 10P 11P 12A 1A 2A 3A 4A 5A 
• A patient on an 8-hour dosing schedule can receive Heparin late. The Heparin can be administered as 
late as 4 hours after the ordered administration time (half the dosing interval). 
o Example: If a dose is given to a patient at 8A, the next dose can be given at 2P.
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Section 5: VTE IPOC 
• Nurses should be familiar with the VTE IPOC and its purpose of providing individualized patient care: 
o Problem, status, interventions, and goals. 
• The nurse will be tasked once a patient is identified as Moderate or High Risk for developing a VTE when the provider completes the risk 
assessment. 
• The VTE IPOC should be completed on admission and then updated throughout hospitalization. 
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Section 5: Documentation: 
• It is critical that nurses fully understand what is expected of them from a documentation standpoint. 
Specifics regarding documentation can be found below. 
 
Pharmacologic Documentation: 
• Pharmacologic documentation should occur in the EMAR for the patient. 
• Below are possible categories for missed doses and examples of what documentation is considered 
acceptable: 
o Not Done: Pt Refusal: Provider (by name) notified/aware, patient education, and reason for 
refusal should be included for each dose being refused. The first refusal should always have a 
provider notified, while subsequent refusals should keep the current provider aware of the 
refusal. If the patient will not disclose why he or she is refusing, “Unknown why patient is 
refusing” would be sufficient. 
o Not Done: D/C Order: No comment needed. 
o Not Done: Order/Task Duplication: No comment needed. 
o Not Done: Not Appropriate at this Time (Details in Comments): Must provide reason for 
missed dose for each instance. 
o Not Done: Held Per MD: Must provide reason for missed dose for each instance as well as 
provider name. 
o Not Done: Pt Unavailable/Off Unit: Must state that this dose is past ½ the interval between 
current and next dose. 
o Not Done: Held for Procedure: Must state “Verified by provider (by name) for procedure (state 
procedure).” 
o Not Done: Other: Must provide reason for missed dose for each instance. 
SCDs: 
• 3x per day (4A, 12P, and 8P): SCDs must be documented applied/intact, refused, or other (reason) for 
SCDs. 
o Note: Comments should be included for anything except for applied/intact. 
o Note: Removal documentation will not count towards 3x per day. 
• Active DVT: SCDs can be applied to unaffected leg if appropriate: 
o Note: Document as one leg applied/intact, one leg as removed, and “Other: [Reason]” 
• At the end of your shift, you must document the time that SCDs have been worn. If your patient is 
refusing SCDs, you need to document 0000/1200 in the “Other” section of "Treatment" under Care 
Interventions. 
Ambulation: 
• 2x per day. 
• Refusals or issues with ambulating the patient should be documented under “Other.” 
• Documentation of distance must occur under “Distance Ambulated:” 
o Note: Distances of less than 32 feet are not considered ambulation. 
o Note: No documentation of distance will assume 0-20 feet, and thus not be considered 
ambulation. 
Education: 
• Initial education should be completed under the VTE/Anticoagulation education. 
• Reeducation can be completed within the “other” comments for their respective areas (see above).  
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Correctly Documenting Missed Doses: 
 
 
Correctly Documenting SCDs: 
 
 
 
 
 
 
 
 
Left leg is marked as intact. Right leg was removed 
due to DVT. A comment was used to reflect this 
contraindication under “Other.” 
Additionally, the reason for refusal should be 
included in this comment for a missed dose. 
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Correctly Documenting SCDs (Continued): 
 
 
  
The amount of time the SCD was 
intact is correctly documented under 
“Other” within “Sequential 
Compression Device.” 
This was the first instance of a patient refusal. 
Proper documentation (physician notification [by 
name] and patient education) for refusals provided 
under “Other.” 
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Correctly Documenting Ambulation: 
 
 
  
Ambulation should be marked under 
activity. 
Distance should be marked under 
“Distance Ambulated.” Anything less than 
32 feet will not be considered ambulation. 
Ambulation was attempted here. The 
nurse commented under “other” to 
document the refusal and education. 
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